Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | CD74 | P04233 | 1/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LPO | P22079 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923937 | 0.88 | IGF1R (0.46) | L3MBTL1HDAC1PTGS2 | |
| SCHEMBL23923798 | 0.87 | CNR1 (0.43) | L3MBTL1PTGS2CNR1CNR2GPR55 | |
| SCHEMBL23923785 | 0.86 | CYP19A1 (0.44) | HDAC1HDAC7MEN1KMT2ACNR1 | |
| SCHEMBL23923990 | 0.82 | PTGS2 (0.48) | PTGS2CNR2 | |
| SCHEMBL23924107 | 0.79 | PTGS2 (0.42) | PTGS2CNR1CNR2 | |
| SCHEMBL23923724 | 0.77 | L3MBTL1 (0.48) | L3MBTL1PTGS2MEN1KMT2ACNR1 | |
| SCHEMBL4817193 | 0.72 | CHRM2 (0.63) | L3MBTL1HDAC1PTGS2 | |
| SCHEMBL9747684 | 0.71 | PPARG (0.61) | HDAC1EPHX2 | |
| SCHEMBL9796229 | 0.71 | PPARG (0.61) | HDAC1EPHX2 | |
| SCHEMBL17509808 | 0.71 | PPARG (0.61) | HDAC1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12091389-B2 | Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1 | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-09-17 | — | — | US | disclosed |
| EP-3901142-A1 | PYRAZOLYLBENZENE-1,3-DIOLS FOR DISEASES ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 18 AND IN COMBINATION WITH TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2021-10-27 | — | — | EP | disclosed |
| US-20210323927-A1 | PYRAZOLYLBENZENE-1,3-DIOLS FOR DISEASES ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 18 AND IN COMBINATION WITH TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323927-A1 | PYRAZOLYLBENZENE-1,3-DIOLS FOR DISEASES ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 18 AND IN COMBINATION WITH TRANSIENT RECEPTOR POTENTIAL VANILLOID 1 | GPR18, TRPV1, TRPV3 | L3MBTL1 4214/4885HDAC1 1766/4885HDAC7 3207/4885 |
| US-12091389-B2 | Pyrazolylbenzene-1,3-diols for diseases associated with g protein-coupled receptor 18 and in combination with transient receptor potential vanilloid 1 | GPR18, TRPV1, TRPV3 | L3MBTL1 4214/4885HDAC1 1766/4885HDAC7 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.